Diagnostics of anti-MAG antibody polyneuropathy

Franciotta, Diego; Gastaldi, Matteo; Benedetti, Luana; Garnero, Martina; Biagioli, Tiziana; Brogi, Marco; Costa, Gianna; Fadda, Elisabetta; Andreetta, Francesca; Simoncini, Ornella; Giannotta, Claudia; Bazzigaluppi, Elena; Fazio, Raffaella; Bedin, Roberta; Ferraro, Diana; Mariotto, Sara; Ferrari, Sergio; Galloni, Elisabetta; Riva, Valentina; Zardini, Elisabetta; Cortese, Andrea; Nobile‐Orazio, Eduardo

doi:10.1007/s10072-017-3024-4

Cited by 7 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgM-associated neuropathy is a common problem in practice. In most instances, the pathophysiology involves an IgM monoclonal protein that binds to the myelin sheath and causes demyelination and widened myelin lamellae 26 . The IgM has antiganglioside antibody activity in 35% of patients; 40–50% have an IgM that binds to myelin-associated glycoprotein.…”

Section: Immunologic Disorders Associated With Monoclonal Igm Proteinmentioning

confidence: 99%

Waldenström macroglobulinemia treatment algorithm 2018

Gertz

2018

Blood Cancer J.

View full text Add to dashboard Cite

Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma. Recent introduction of MYD88 mutational analysis has been very useful for diagnostic purposes but is unclear what effect it might have on the prognosis or response rate to therapy. An algorithm is provided on the management of asymptomatic individuals and the sequence used for chemotherapeutic intervention of symptomatic patients.

show abstract

Section: Immunologic Disorders Associated With Monoclonal Igm Proteinmentioning

confidence: 99%

Waldenström macroglobulinemia treatment algorithm 2018

Gertz

2018

Blood Cancer J.

View full text Add to dashboard Cite

show abstract

“…Considering the presence of some variability in the assessment measures, the Italian Neuroimmunological Society, recently recommended that each Centre should calculate its own cutoff level for diagnostic confirmation (Franciotta et al, 2017).…”

Section: It Also Has the Advantage Of Facilitating The Interpretation...mentioning

confidence: 99%

Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy

Liberatore

Giannotta

Sajeev

et al. 2020

Journal of Neuroimmunology

Self Cite

View full text Add to dashboard Cite

“…Diagnosis rests upon this typical clinical and electrophysiological spectrum, the presence of immunoglobulin M (IgM) monoclonal gammopathy and an increased titer of serum anti-MAG antibodies [3,4]. Specific diagnostic criteria for anti-MAG neuropathy, beside the presence of high titers of anti-MAG antibodies, have not been established, however.…”

Section: Introductionmentioning

confidence: 99%

“…Nerve conduction studies reveal sensory abnormalities compatible with demyelination and abnormally increased distal latencies in motor nerves, whilst motor nerve conduction blocks are uncommon [ 2] . Diagnosis rests upon this typical clinical and electrophysiological spectrum, the presence of immunoglobulin M (IgM) monoclonal gammopathy and an increased titer of serum anti‐MAG antibodies [ 3 , 4 . Specific diagnostic criteria for anti‐MAG neuropathy, beside the presence of high titers of anti‐MAG antibodies, have not been established, however.…”

Section: Introductionmentioning

confidence: 99%

A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody

Doneddu

Ruiz

Bianchi

et al. 2022

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

Background and purpose:A diagnostic score was developed to discriminate anti-myelinassociated-glycoprotein (MAG) neuropathy from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and applied it to patients with atypical anti-MAG neuropathy. Methods:The clinical and electrophysiological features of patients with a diagnosis of typical anti-MAG neuropathy were compared to those of patients with a diagnosis of CIDP. The association of each feature with the diagnosis was assessed in the two groups.Features showing a significant association with the diagnosis were included in a multivariable logistic regression model and adjusted odds ratios were estimated for each feature.A score ranging from 1 to 3 was applied to each feature based on the magnitude of the estimated odds ratios. The score was then applied to patients with a clinical diagnosis of CIDP who also had high anti-MAG antibody titers (CIDP-MAG).Results: Thirty-one anti-MAG neuropathy patients, 45 typical CIDP patients and 16 CIDP-MAG patients were included. Scores in anti-MAG antibody patients ranged from 1 to 5 and in CIDP patients from −7 to −1. Using the score, 4/16 CIDP-MAG patients were diagnosed to have anti-MAG neuropathy and 12/16 patients to have CIDP. Response to intravenous immunoglobulin in the CIDP-MAG patients classified as CIDP was similar to that of definite CIDP patients and higher than that of anti-MAG neuropathy patients. Conclusions:Our score allowed an accurate discrimination to be made, amongst patients with anti-MAG antibodies, of those affected by CIDP and the patients with anti-MAG neuropathy. This score may help proper treatment to be chosen for patients with anti-MAG antibodies with a CIDP-like presentation.

show abstract

Diagnostics of anti-MAG antibody polyneuropathy

Cited by 7 publications

References 10 publications

Waldenström macroglobulinemia treatment algorithm 2018

Waldenström macroglobulinemia treatment algorithm 2018

Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy

A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody

Contact Info

Product

Resources

About